Abstract:Background: Despite the benefits of mesenchymal stromal cell (MSC) transplantation in cardiac tissue, detailed in vivo observations have shown that MSCs only survive for a brief period after transplantation due to harsh microenvironmental conditions, including ischemia, inflammation and anoikis, in the infarcted myocardium. Thus, new strategies are needed to enhance MSC survival and inhibit cardiac remodeling. Studies have now demonstrated that chemokine [C-C motif] ligand 2 (CCL2) and its cognate receptor C-C chemokine receptor 2 (CCR2) promote excessive Ly6C(high) inflammatory monocyte infiltration at the infarct in response to ischemic myocardial injury. Therefore, decreasing the activities of these monocytes immediately after acute myocardial infarction (AMI) could be beneficial for AMI patients. Objectives: This study tested the hypothesis that therapeutic siRNA-loaded photoluminescent mesoporous silicon nanoparticles (PMSNs) targeting CCR2 expression in Ly6C(high) inflammatory monocytes decrease the accumulation of these cells in the infarct, improve the efficacy of MSC transplantation and attenuate myocardial remodeling.Methods: PMSNs carrying therapeutic siCCR2 were first synthesized without the inclusion of fluorescent materials or dyes. After AMI BALB/c mice were established, 10(5) 5-ethynyl-2'- deoxyuridine (EdU)-labeled MSCs suspended in 100 mu l of phosphate buffered saline (PBS) were injected into the border zone of the infarct of each mouse. PMSNs-siCCR2 (25 mu g/g) were also intravenously injected via the tail vein immediately following AMI induction. Control mice were injected with an equal amount of PMSNs without siCCR2. PMSNs-siCCR2 were examined in vivo using near-infrared imaging technology. The therapeutic effects of PMSNs-siCCR2 for MSC transplantation were determined at the mRNA, protein and functional levels.Results: PMSNs-siCCR2 circulated freely in vivo and were cleared in a relatively short period of time (t(1/2) = 37 min) with no evidence of toxicity. The therapeutic PMSNs-siCCR2 showed higher levels of cellular accumulation in Ly6C(high) monocytes in the spleen and more efficient degradation of CCR2 compared with the control (8.04%+/- 2.17% vs. 20.02%+/- 4.55%, p<0.001). Subsequently, the PMSNs-siCCR2 decreased the accumulation of CD11b-positive monocytes at the infarct (49.3%+/- 17.34% vs. 61.32%+/- 22.43%, p<0.001) on day 1. Increased survival of transplanted MSCs (13 +/- 3/mm(2) vs. 4 +/- 1/mm(2), p<0.001) and significantly decreased TdT-mediated dUTP nick end labeling (TUNEL)(+) cardiac myocytes (17.44%+/- 6.26% vs. 39.49%+/- 13.28%, p<0.001) were then identified in the infarct zone three days after AMI induction in the PMSNs-siCCR2 group. Three weeks after MSC injection, significant increases were observed in the vascular density (235.5 +/- 39.6/mm(2) vs. 147.4 +/- 20.3/mm(2), p<0.001) and the cardiac myosin-positive area (21.7%+/- 8.4% vs. 13.2%+/- 4.4%, p<0.001) of the infarct border zone. In addition, significant amelioration of left ventricular (LV) remodeling (thickness of the LV posterior walls) (0.84 +/- 0.11 mm vs. 0.61 +/- 0.08 mm, p<0.001) was also observed at the same time compared with the control group.Conclusions: PMSNs-siCCR2-mediated CCR2 gene silencing in Ly6C(high) monocytes improved the effectiveness of MSC transplantation and selectively ameliorated myocardial remodeling after AMI. These results suggest that PMSNs-siCCR2 could potentially be used to develop an anti-inflammatory therapy for post-AMI MSC transplantation.

Sirna Delivery Against Myocardial Ischemia Reperfusion Injury Mediated by Reversibly Camouflaged Biomimetic Nanocomplexes

Inhibition of Neointimal Hyperplasia in Balloon-Induced Vascular Injuries in a Rat Model by Mir-22 Loading Laponite Hydrogels.

MicroRNA-208a silencing against myocardial ischemia/reperfusion injury mediated by reversibly camouflaged biomimetic nanocomplexes

Macrophage-targeting gene silencing orchestrates myocardial microenvironment remodeling toward the anti-inflammatory treatment of ischemia-reperfusion (IR) injury

Biomimetic Nanocomplexes Orchestrate Post-Stroke Cerebral Microenvironment Via Microglia-Targeted Sirna Delivery

Bioreducible, Branched Poly(β-Amino Ester)s Mediate Anti-Inflammatory ICAM-1 Sirna Delivery Against Myocardial Ischemia Reperfusion (IR) Injury

A Novel Ultrasound‐Responsive Biomimetic Nanoparticle for Targeted Delivery and Controlled Release of Nitric Oxide to Attenuate Myocardial Ischemia Reperfusion Injury

An in Vivo Mirna Delivery System for Restoring Infarcted Myocardium.

Engineered Macrophage Membrane‐Coated S100A9‐siRNA for Ameliorating Myocardial Ischemia‐Reperfusion Injury

Delivery of SAV-siRNA via Exosomes from Adipose-Derived Stem Cells for the Treatment of Myocardial Infarction

Endothelial cell-targeting, ROS-ultrasensitive drug/siRNA co-delivery nanocomplexes mitigate early-stage neutrophil recruitment for the anti-inflammatory treatment of myocardial ischemia reperfusion injury

Cardiomyocyte-targeted Anti-Inflammatory Nanotherapeutics Against Myocardial Ischemia Reperfusion (IR) Injury

Functionalized Dendrimer-Based Delivery of Angiotensin Type 1 Receptor Sirna for Preserving Cardiac Function Following Infarction

Nanovector-based Prolyl Hydroxylase Domain 2 Silencing System Enhances the Efficiency of Stem Cell Transplantation for Infarcted Myocardium Repair.

Hippo pathway-manipulating neutrophil-mimic hybrid nanoparticles for cardiac ischemic injury via modulation of local immunity and cardiac regeneration

Direct in Vivo Reprogramming with Non-Viral Sequential Targeting Nanoparticles Promotes Cardiac Regeneration.

Photoluminescent Mesoporous Silicon Nanoparticles With Siccr2 Improve The Effects Of Mesenchymal Stromal Cell Transplantation After Acute Myocardial Infarction

Biomimetic nanoplatform treats myocardial ischemia/reperfusion injury by synergistically promoting angiogenesis and inhibiting inflammation

Spherical Α-Helical Polypeptide-Mediated E2F1 Silencing Against Myocardial Ischemia-Reperfusion Injury (MIRI).

Nanoparticle-Patch System for Localized, Effective, and Sustained miRNA Administration into Infarcted Myocardium to Alleviate Myocardial Ischemia-Reperfusion Injury

Reprogramming monocytes into M2 macrophages as living drug depots to enhance treatment of myocardial ischemia-reperfusion injury